Your browser doesn't support javascript.
loading
Cardiac Manifestations of Systemic Lupus Erythematous: An Overview of the Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology and Treatment Options.
Zagelbaum Ward, Nicole K; Linares-Koloffon, Carlos; Posligua, Alba; Gandrabur, Liliya; Kim, Woo Young; Sperber, Kirk; Wasserman, Amy; Ash, Julia.
Afiliação
  • Zagelbaum Ward NK; From the Department of Rheumatology, Keck School of Medicine/University of Southern California, Los Angeles, CA.
  • Linares-Koloffon C; Yale Center for Asthma and Airway Disease, Yale University School of Medicine, New Haven, CT.
  • Posligua A; Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
  • Gandrabur L; Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
  • Kim WY; Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
  • Sperber K; Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
  • Wasserman A; Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
  • Ash J; Department of Medicine and Division of Rheumatology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Cardiol Rev ; 30(1): 38-43, 2022.
Article em En | MEDLINE | ID: mdl-32991394
ABSTRACT
Systemic lupus erythematosus (SLE) is a complex connective tissue disease that can potentially affect every organ of the human body. In some cases, SLE may present with diverse cardiac manifestations including pericarditis, myocarditis, valvular disease, atherosclerosis, thrombosis, and arrhythmias. Heart disease in SLE is associated with increased morbidity and mortality. It is unclear whether traditional treatments for coronary artery disease significantly impact mortality in this population. Current therapeutic agents for SLE include glucocorticoids, hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, and B cell-directed therapies. This article will provide a comprehensive review and update on this important disease state.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiopatias / Lúpus Eritematoso Sistêmico Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Cardiol Rev Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiopatias / Lúpus Eritematoso Sistêmico Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Cardiol Rev Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá